Evidence map›Paper›PMID 35864037›Full record

ArticleResearch in social & administrative pharmacy : RSAP2022

Thromboprophylaxis and clinical outcomes in moderate COVID-19 patients: A comparative study.

Asmaa S Mohamed, Hosam M Ahmad, Alyaa S A Abdul-Raheem, Fatma M M Kamel, Ali Khames, Ahmed F Mady

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Research in social & administrative pharmacy : RSAP, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Efficacy and Safety of Direct Oral Anticoagulants Compared With Heparin for Preventing Thromboembolism in Hospitalized Patients With COVID-19: A Systematic Review and Meta-Analysis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Pooled it
  3. Trial
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Asmaa S MohamedClinical Pharmacy Department, Faculty of Pharmacy, Port Said University, Port Said, Egypt. Electronic address: Asmaa.Mohamed@pharm.psu.edu.eg.
Hosam M AhmadInternal Medicine and Biomedical Chemistry Department, Egypt Ministry of Health and Population. Minia, Egypt. Electronic address: hosam.mohammed@psas.bsu.edu.eg.
Alyaa S A Abdul-RaheemClinical Pharmacy Department, Faculty of Pharmacy, Deraya University, Minia, Egypt. Electronic address: alyaa.khateeb@gmail.com.
Fatma M M KamelInternal Medicine Department, Faculty of Medicine, Minia University, Minia, Egypt. Electronic address: fatma.kamel@mu.edu.eg.
Ali KhamesPharmacology and Toxicology Department, Faculty of Pharmacy, Sohag University, Sohag, Egypt. Electronic address: ali.khames@pharm.sohag.edu.eg.
Ahmed F MadyChest Department, Faculty of Medicine, Minia University, Minia, Egypt. Electronic address: ahmed.mady@mu.edu.eg.
Minia University · EGDeraya UniversityMinistry of Health and Population · EGPort Said University · EGSohag University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMany thrombotic complications are linked to coronavirus disease 2019 (COVID-19). Antithrombotic treatments are important for prophylaxis against these thrombotic events.

objectivesThis study was designed to compare enoxaparin and rivaroxaban as prophylactic anticoagulants in moderate cases of COVID-19 in terms of efficacy, safety, and clinical outcomes.

methodsThe study involved 124 patients with moderate COVID-19 (pneumonia without hypoxia) divided into two groups. The first group (G1) comprised 66 patients who received enoxaparin subcutaneously at a dose of 0.5 mg/kg every 12 h until discharge from the hospital. The second group (G2) comprised 58 patients who received oral rivaroxaban at a dose of 10 mg once daily until discharge from the hospital. The outcomes evaluated in this study were as follows: intermediate care unit (IMCU) duration, the number of patients transferred from the IMCU to the intensive care unit (ICU), ICU duration, the total length of hospital stay, in-hospital mortality, and thrombotic and bleeding complications.

resultsNo significant differences in IMCU duration (p = 0.39), ICU duration (p = 0.96), and total length of hospital stay (p = 0.73) were observed between the two groups. The percentage of patients requiring ICU admission after hospitalization was 21.2% in G1 and 22.4% in G2 (p = 0.87). The mortality rate was 12.1% in G1 and 10.3% in G2 (p = 0.76). The proportion of patients who had thrombotic complications was 9.1% in G1 and 12.1% in G2 (p = 0.59). The incidence of mild bleeding was 3% in G1 and 1.7% in G2 (p = 0.64).

conclusionEither enoxaparin or rivaroxaban may be used as thromboprophylaxis agents in managing patients with moderate COVID-19. Either medication has no clear advantage over the other.

Indexed as

COVID-19Venous ThromboembolismAnticoagulantsEnoxaparinHumansRivaroxabanAnticoagulantsEnoxaparinRivaroxabanAnticoagulantsCOVID-19EnoxaparinRivaroxabanThromboprophylaxis

Identifiers

PMID35864037
PMCPMC9288247
OpenAlexW4285679074

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.